Trials / Recruiting
RecruitingNCT06181513
Probiotics in Mild Alzheimer's Disease
Effect of Probiotics on Cognitive Functioning of Patients With Mild Alzheimer's Disease
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- University of Nicosia · Academic / Other
- Sex
- All
- Age
- 65 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The main objective is to investigate whether administration of probiotics to patients with mild Alzheimer's Disease (AD) reduces neuroinflammation, improves cognitive function and modifies neurophysiological measures, compared to a patient group that receives placebo (no active probiotics).
Detailed description
We will measure specific blood inflammatory markers (primary outcome), neurophysiological activity, cognitive test scores, microbiome composition and dietary habits of participants in the probiotics and placebo group.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Probiotic Blend Capsule | 20 million CFU (Lactobacillus paracasei, Lactobacillus plantarum, Lactobacillus rhamnosus, Lactobacillus helveticus, Bifidobacterium breve) |
Timeline
- Start date
- 2022-12-19
- Primary completion
- 2025-07-01
- Completion
- 2025-12-01
- First posted
- 2023-12-26
- Last updated
- 2024-12-05
Locations
1 site across 1 country: Cyprus
Source: ClinicalTrials.gov record NCT06181513. Inclusion in this directory is not an endorsement.